Key facts
- OWP Pharmaceuticals’s last known valuation is $10.0M (Aug 2016).
- It has raised $10.0M across 2 recorded rounds; the latest was Seed Round ($2.4M) in Jul 2025.
- Notable investors include MIGMIR, Manna Capital Partners, Talanton, Visionary Private Equity Group.
- OWP Pharmaceuticals has filed 2 Form Ds with the SEC since 2024, most recently Sep 2025 ($2.4M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for OWP Pharmaceuticals
Funding rounds
2 roundsAbout OWP Pharmaceuticals
Developer of food and drug administration (FDA) approved epilepsy medications intended to support patients and healthcare providers in neurology and psychiatry. The company specializes in developing and commercializing novel oral liquid formulations for epilepsy and associated psychiatric disorders, enabling clients to improve the lives of affected and under-resourced patients worldwide at an affordable cost.
- Sector
- Healthcare
- HQ
- Lisle, IL, United States
- Founded
- 2014
- Employees
- 21
- Website
- owppharma.com/
- Ownership
- Privately Held (backing)
OWP Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OWP Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OWP Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.